Giving Compass' Take:

• As the global crisis around Alzheimer’s continues to grow, the private sector is joining the government and nonprofits to address the problem in their markets in hopes to prevent and treat this disease. 

• How do fundraising efforts compare in different countries? How can funders get involved in advancing Alzheimer’s research? 

• Learn about how to make an impact on Alzheimer’s disease therapies. 

As studies show that early diagnosis and preventative therapies can help prevent the onset of Alzheimer’s, startups that are working to diagnose the disease earlier are gaining more attention and funding.

That’s a boon to companies like Neurotrack, which closed on $21 million in new financing led by the company’s previous investor, Khosla Ventures, with participation from new investors Dai-ichi Life and SOMPO Holdings.

In 2018, the Japanese life insurance company Dai-ichi Life partnered with Neurotrack to roll out a cognitive assessment tool to the company’s customers in Japan.

Last year, the Japanese health insurer SOMPOconducted a 16-week pilot with Neurotrack, where more than 550 of SOMPO’s employees took Neurotrack’s test and followed the Memory Health Program for four months. Neurotrack and SOMPO are now working to deepen and extend their partnership.

Read the full article about startups and nonprofits raising money to fight Alzheimer's disease by Jonathan Shieber at TechCrunch.